AMSTERDAM, June 2 (Reuters) - Dutch chemical group Akzo Nobel NV (AKZO.AS: Quote, Profile, Research)(AKZOY.O: Quote, Profile, Research) said on Friday that the U.S. Food and Drug Administration has found the menopause treatment tibolone of its Organon unit “not approvable”. “Although Organon is disappointed with the FDA’s response, we will continue to be committed to this proven brand,” Organon General Manager Toon Wilderbeek said in a statement.
